Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

2024 Annual Meeting | C47 - Diagnosis and Treatment of Multiple Sclerosis in Diverse Populations

Sunday 04/14/24
01:00 PM - 03:00 PM MDT Add To Calendar
Colorado Convention Center | Mile High 2/3
This program will be presented both in-person and online
This program will be available in the meeting's On Demand product.
Seminar
Jaime Imitola, MD, FAAN
Health Care Disparities, Multiple Sclerosis
Participants should gain an understanding of the current data on the incidence and prevalence of MS in diverse populations and unique geographic distributions; the biological principles that underlie the emergent views of pathology and progression of multiple sclerosis among African American, Asian, Hispanic populations, which are the faster-growing demographics in the US; current challenges of health care disparities affecting diverse populations; emerging data of MS throughout the lifespan affecting minorities, i.e., pediatric-onset MS, aging in MS; mimickers, typical and atypical clinical presentations of MS in diverse populations; emerging clinical trial data for RCTs in diverse populations; how MS affects various communities differently and how its diagnosis and treatment present challenges specific to population groups; data from the patient experience and registries; considerations to practicing neurologists of strategies to overcome cultural factors and perceptions from patients and families about MS care to avoid delayed diagnosis or inadequate treatment; and practical strategies to foster patient-centered care in diverse populations, building trust, patient education, self-agency, with opportunities and resources from the AAN to improve care in these populations.
 
This program is supported in part by educational grants from Novartis Pharmaceuticals, Sanofi, and Mylan Specialty L.P., a Viatris Company.
2.00 CME credits
Patient Care & Procedural Skills, Interpersonal and Communication Skills, Professionalism, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice, Quality Improvement
Intermediate
Diversity, Equity, and Inclusion
Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student, Business Administrator
Case-based, Didactic, Audience Participation

Program Materials Program Evaluations

Event Timeline
01:00 PM - 01:15 PM MDT Introduction Diverse Populations with MS as Distinct and Neglected Population
Jaime Imitola, MD, FAAN
01:15 PM - 01:45 PM MDT Speaker Emergent Biology and Social Determinants of MS Onset and Progression in Diverse Populations
Lilyana M. Amezcua, MD, FAAN
01:45 PM - 02:15 PM MDT Speaker Practical Considerations of Diverse MS Care from the Patient Perspectives/Registries
Mitzi Joi Williams, MD, FAAN
02:15 PM - 02:45 PM MDT Speaker Disease-modifying Therapies and Real-world Strategies to improve Care Throughout the Lifespan in Diverse Populations with MS
Jaime Imitola, MD, FAAN
02:45 PM - 03:00 PM MDT Q&A Questions & Answers
Jaime Imitola, MD, FAAN, Mitzi Joi Williams, MD, FAAN, Lilyana M. Amezcua, MD, FAAN
Faculty Disclosures
Jaime Imitola, MD, FAAN Dr. Imitola has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis . The institution of Dr. Imitola has received research support from biogen. Dr. Imitola has a non-compensated relationship as a Board Member with National MS Society that is relevant to AAN interests or activities. Dr. Imitola has a non-compensated relationship as a Committee Member with International Society for Stem Cell Research that is relevant to AAN interests or activities.
Mitzi Joi Williams, MD, FAAN Dr. Williams has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen Idec. Dr. Williams has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis Pharmaceuticals. Dr. Williams has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Williams has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Williams has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genzyme. Dr. Williams has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for TG Therapeutics. Dr. Williams has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Williams has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Williams has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Horizon Therapeutics. Dr. Williams has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Williams has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Williams has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Williams has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Williams has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genzyme. Dr. Williams has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Williams has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Williams has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. Dr. Williams has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Dr. Williams has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen Idec. Dr. Williams has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Williams has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Genentech. Dr. Williams has received publishing royalties from a publication relating to health care. Dr. Williams has received publishing royalties from a publication relating to health care. Dr. Williams has a non-compensated relationship as a National Board Member with National MS Society that is relevant to AAN interests or activities.
Lilyana M. Amezcua, MD, FAAN Dr. Amezcua has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for serono. Dr. Amezcua has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Amezcua has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Amezcua has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for genentech. The institution of Dr. Amezcua has received research support from National MS Society. The institution of Dr. Amezcua has received research support from Genentech. The institution of Dr. Amezcua has received research support from Medday. The institution of Dr. Amezcua has received research support from Bristol Myers Squibb Foundation. The institution of Dr. Amezcua has received research support from NIH NINDS.